12:00 AM
Oct 19, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Amonafide: Phase III amend

Antisoma will amend the ongoing, open-label Phase III ACCEDE trial evaluating AS1413 to change the primary endpoint to initial remission rate from confirmed remission (CR) rate in order to remove the need to confirm remission before further intervention and reduce the need...

Read the full 189 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >